Everest Organics Share Price | Everest Organics Stock Screener
EVERESTO
Pharmaceuticals
Share Price BSE
₹273.70
▲
3.25 (1.20%)
As of July 6, 2026, the Everest Organics share price (BSE: EVERESTO) is ₹273.70, up 1.20% from the previous close, with shares trading between ₹267.15 and ₹275.00, and a 52-week range of ₹203.45–₹522.50.
Analyse EVERESTO share price data and track historical price performance.
Use the Everest Organics stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Everest Organics Market Cap
₹262.60 Cr.
EVERESTO P/E Ratio (TTM)
47.36
Everest Organics P/B Ratio
3.48
EPS (TTM)
₹5.70
Dividend Yield
-
Debt to Equity
0.91
EVERESTO 52 Week High
₹522.50
Everest Organics 52 Week Low
₹203.45
Operating Margin
10.00%
Profit Margin
3.06%
EVERESTO Revenue (TTM)
₹196.00
EBITDA
₹20.00
Net Income
₹6.00
Total Assets
₹240.00
Total Equity
₹76.00
Everest Organics Share Price Chart
Screen Everest Organics share price with an interactive chart. Analyse EVERESTO price trends and volatility across different timeframes.
Everest Organics Company Profile - Fundamental Screener
Screen Everest Organics company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for EVERESTO shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE334C01029
Everest Organics Balance Sheet Screener
Screen EVERESTO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 240 | 225 | 227 | 202 | 178 | 135 | 120 | 107 | 94 | 86 |
| Current Assets | 167 | 148 | 150 | 133 | 118 | 89 | 79 | 67 | 58 | 49 |
| Fixed Assets | 68 | 50 | 52 | 55 | 49 | 44 | 39 | 39 | 34 | 33 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 12 | 15 | 21 | 18 | 19 | 11 | 12 | 10 | 8 | 7 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 76 | 70 | 46 | 46 | 47 | 47 | 34 | 26 | 19 | 16 |
| Share Capital | 10 | 10 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves & Surplus | 66 | 59 | 38 | 38 | 39 | 39 | 26 | 18 | 11 | 8 |
Everest Organics Income Statement Screener - Profit & Revenue Analysis
Screen Everest Organics income statement and profit fundamentals.
Analyze EVERESTO quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Everest Organics share price evaluation.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 196 | 160 | 198 | 190 | 202 | 183 | 169 | 156 | 113 | 108 | 100 | 107 |
| Expenses | 176 | 152 | 186 | 182 | 194 | 159 | 148 | 138 | 105 | 101 | 94 | 98 |
| EBITDA | 20 | 8 | 12 | 8 | 9 | 24 | 21 | 18 | 8 | 7 | 6 | 8 |
| Operating Profit % | 10.00% | 5.00% | 6.00% | 1.00% | 3.00% | 13.00% | 11.00% | 11.00% | 6.00% | 6.00% | 6.00% | 7.00% |
| Depreciation | 6 | 6 | 6 | 5 | 4 | 3 | 3 | 3 | 3 | 2 | 3 | 3 |
| Interest | 7 | 5 | 6 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit Before Tax | 8 | -3 | 1 | 0 | 2 | 17 | 14 | 12 | 2 | 2 | 0 | 2 |
| Tax | 2 | -2 | 1 | 0 | 1 | 4 | 3 | 5 | 1 | 0 | 0 | 0 |
| Net Profit | 6 | -1 | 0 | 0 | 1 | 14 | 11 | 8 | 2 | 1 | 0 | 2 |
| EPS | 5.70 | -2.97 | 0.17 | -0.23 | 1.43 | 17.14 | 13.62 | 9.39 | 2.14 | 1.69 | 0.54 | 1.78 |
Everest Organics Cash Flow Screener - Liquidity Fundamentals
Screen EVERESTO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -5 | 16 | 18 | 14 | 14 | 10 | 9 | 5 | 10 | 7 |
| Investing Activities | -5 | -13 | -16 | -17 | -12 | -6 | -5 | -4 | -8 | -7 |
| Financing Activities | 16 | -3 | -3 | 2 | -2 | -3 | -3 | -1 | -2 | 0 |
| Net Cash Flow | 6 | 0 | 0 | -1 | 0 | 0 | 1 | 0 | 0 | 0 |
Everest Organics Shareholding Pattern Screener
See Everest Organics shareholding pattern with promoter, FII, and DII holdings.
Check Everest Organics promoter holding and ownership changes for EVERESTO on TickJournal.
| Item | 2026-Mar | 2025-Jan | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 59.58% | 61.09% | 61.09% | 60.99% | 59.64% | 59.61% | 74.15% | 74.15% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.06% | 0.06% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 26.91% | 32.22% | 23.87% | 25.35% | 25.98% | 26.10% | 20.00% | 20.05% |
| Other Holding | 13.48% | 6.67% | 15.02% | 13.64% | 14.35% | 14.26% | 5.79% | 5.75% |
| Shareholder Count | 7,880 | 8,795 | 8,756 | 8,281 | 8,079 | 7,804 | 10,023 | 9,792 |
Everest Organics Share Dividend Screener - Share Yield Analysis
Check Everest Organics dividend history with payout and yield data.
View Everest Organics dividend details including ex-dates and amounts for EVERESTO stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹1.50 | 0.86% |
| 2020-March | ₹1.00 | 0.43% |
| 2019-March | ₹1.00 | 1.05% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Everest Organics Stock Index Membership
See which indices include Everest Organics stock.
Check EVERESTO index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Everest Organics Market Events Screener - Corporate Actions
Get Everest Organics corporate actions including splits, bonuses, and buybacks.
Check Everest Organics stock events that may affect EVERESTO share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 25.93% | ||
| Dividend | ₹ 1.00 /share | -16.77% | ||
| Dividend | ₹ 0.50 /share | -6.05% | ||
| Annual General Meeting | NA | -3.38% | ||
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 3.65% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | -0.90% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | 0.21% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | -5.94% |
| 2025-05-27 | 2025-05-27 | Quarterly Result Announcement | NA | 7.42% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 0.76% |
| 2025-01-08 | 2025-01-08 | Extraordinary General Meeting | NA | 36.35% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -6.74% |
| 2021-02-17 | 2021-02-18 | Dividend | ₹ 0.50 /share | -9.19% |
Everest Organics Competitors Screener - Peer Comparison
Screen EVERESTO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 457,577 | 39.71 | 58,220 | 6.38% | 11,565 | 69.58 |
| Divis Laboratories | 180,386 | 69.89 | 10,560 | 8.73% | 2,520 | 55.41 |
| Torrent Pharmaceuticals | 161,337 | 75.43 | 13,886 | 20.34% | 2,138 | 70.39 |
| Cipla | 118,026 | 30.51 | 29,045 | 2.24% | 3,870 | 66.80 |
| Zydus Life Science | 114,660 | 22.41 | 26,720 | 13.65% | 5,242 | 66.88 |
| Dr Reddys Laboratories | 114,441 | 27.60 | 35,059 | 3.90% | 4,158 | 67.04 |
| Lupin | 113,723 | 21.14 | 27,488 | 19.98% | 5,345 | 71.73 |
| Mankind Pharma | 104,158 | 53.93 | 14,278 | 12.03% | 1,750 | 60.79 |
| Aurobindo Pharma | 93,148 | 26.86 | 33,385 | 3.21% | 3,376 | 70.76 |
| Laurus Labs | 83,019 | 93.55 | 6,868 | 22.01% | 890 | 71.63 |
Everest Organics Company Announcements - News Screener
Screen EVERESTO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-06-24 | Closure of Trading Window | - |
| 2026-06-22 | Announcement under Regulation 30 (LODR)-Cessation | - |
| 2026-06-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-29 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-05-29 | Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. May 29 2026. | - |
| 2026-05-29 | Audited Financials Results For The Quarter And Year Ended March 31 2026. | - |
| 2026-05-23 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-21 | Board Meeting Intimation for Meeting Scheduled To Be Held On 29Th May 2026. | - |
| 2026-04-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-03-23 | Closure of Trading Window | - |
| 2026-03-06 | Disclosure Of Reasons For Delay In Submission Of Financial Results For The Quarter Ended December 31 2025 Under Regulation 33 Of SEBI (LODR) Regulations 2015 | - |
| 2026-02-16 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-15 | Unaudited Financial Results For The Quarter Ended And Nine Months Ended December 31 2025. | - |
| 2026-02-15 | Board Meeting Outcome for Outcome Of Board Meeting Dated February 14 2026 - Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-02-15 | Board Meeting Outcome for Outcome Of Board Meeting Dated February 14 2026 - Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-02-14 | Newspaper Publication | - |
| 2026-02-12 | Board Meeting Intimation for Intimation Regarding Postponement And Rescheduling Of Board Meeting. | - |
| 2026-02-03 | Board Meeting Intimation for Un-Audited Financial Results Along With The Limited Review Report Of The Company For The Quarter Ended December 31 2025. | - |
| 2026-01-22 | Report On Re-Lodgement Of Transfer Request Of Physical Shares | - |